Ironwood Pharmaceuticals (IRWD) Restructuring Costs (2018 - 2026)

Ironwood Pharmaceuticals has disclosed Restructuring Costs across 8 years of filings, most recently posting -$40000.0 for Q1 2026.

• In Q1 2026, Restructuring Costs fell 100.22% year-over-year to -$40000.0; the TTM figure through Jun 2026 stood at $1.9 million (down 89.63% YoY), while the FY2025 annual figure was $20.3 million, up 681.22% from the prior year.
• Restructuring Costs came in at -$40000.0 for Q1 2026 at Ironwood Pharmaceuticals, up from -$252000.0 in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $18.6 million in Q1 2025 to a low of -$252000.0 in Q4 2025.
• Average Restructuring Costs over 4 years is $3.4 million, with a median of $529000.0 recorded in 2023.
• The largest YoY upside for Restructuring Costs was 13650.0% in 2025 against a maximum downside of 445.21% in 2025.
• Over 4 years, Restructuring Costs stood at $621000.0 in 2023, then sank by 88.24% to $73000.0 in 2024, then tumbled by 445.21% to -$252000.0 in 2025, then soared by 84.13% to -$40000.0 in 2026.
• Per Business Quant data, the three most recent Restructuring Costs figures were -$40000.0 in Q1 2026, -$252000.0 in Q4 2025, and $2.2 million in Q3 2025.